Overview

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

Status:
Completed

Trial end date:
2019-07-20

Target enrollment:

Participant gender:

Summary

This is a Phase 1, randomized study to evaluate the rate of nausea in healthy premenopausal study participants following a single dose of BMT with or without a single 8 mg po dose of Zofran given 30 minutes before BMT dosing.

Phase:

Phase 1

Details

Lead Sponsor:

AMAG Pharmaceuticals, Inc.

Treatments:

alpha-MSH
Ondansetron